Ixchelsis Gets $14M for Premature Ejaculation Drug
By Cormac Sheridan
Tuesday, August 6, 2013
Ixchelsis Ltd., a start-up with roots in Pfizer Inc.'s UK R&D facility at Sandwich, in Kent, has raised more than $14 million from TVM Life Science Ventures VII fund for development of an oxytocin antagonist, IX-01, for treating premature ejaculation.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.